CLINICAL TRIALS PROFILE FOR OPDUALAG
✉ Email this page to a colleague
All Clinical Trials for OPDUALAG
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05704933 ↗ | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Recruiting | Bristol-Myers Squibb | Early Phase 1 | 2023-01-19 | The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug. |
| NCT05704933 ↗ | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | Early Phase 1 | 2023-01-19 | The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug. |
| NCT06101134 ↗ | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | Recruiting | Bristol-Myers Squibb | Phase 2 | 2023-11-08 | The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC. |
| NCT06151236 ↗ | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | Recruiting | Bristol-Myers Squibb | Phase 2 | 2024-03-11 | The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival |
| NCT06151236 ↗ | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | Recruiting | Melanoma Institute Australia | Phase 2 | 2024-03-11 | The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival |
| NCT06246916 ↗ | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | RECRUITING | Regeneron Pharmaceuticals | PHASE3 | 2024-09-09 | This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OPDUALAG
Condition Name
Clinical Trial Locations for OPDUALAG
Trials by Country
Clinical Trial Progress for OPDUALAG
Clinical Trial Phase
Clinical Trial Sponsors for OPDUALAG
Sponsor Name
